ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Status:
Completed
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
Our study will compare all kidney transplant recipients receiving valganciclovir vs.
valacyclovir for one year following kidney transplant and compare:
1. the incidence, magnitude and duration of CMV and EBV viremia in the first year after
transplant.
2. the side effects of the anti-viral drugs requiring dose reduction or cessation
In addition, we will test renal tissue obtained from any biopsies post-transplant
(surveillance or clinically indicated biopsies) by both polymerase chain reaction (PCR) and
fluorescence in situ hybridization to assess for latent CMV and/or EBV.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute